Recheck five things, in this order: the expiry date on the member’s own authorization, whether the plan year rolled over, whether the drug list was revised, whether the required dispensing channel changed, and whether the employer altered the benefit. Each runs on a separate calendar, and all five look identical at the pharmacy counter.
Why one rejection has five possible causes
A drug benefit is assembled from parts owned by different parties. The plan sponsor buys the design. A pharmacy benefit manager maintains the drug list and the review criteria. A carrier administers the coverage. Pharmacies dispense under network contracts. Aetna is a CVS Health company and CVS Caremark belongs to the same group, so several of those parts can share a parent while still moving on unrelated schedules.
The register gives back the same short message whichever part moved, so guesswork fills the gap and the guess is usually wrong. Weeks get spent chasing a drug list revision that never happened while a lapsed approval waits for one form. Working down the list in order of likelihood beats reasoning about it.
First: the authorization on file
Approvals carry an end date and a continuation request is a fresh clinical review, not a renewal that happens by itself. Reauthorization typically asks what the treatment has achieved and whether it is still being taken as written. No warning goes out when the date passes, so the first sign is a pharmacy telling someone the claim will not go through.
Closing this one is administrative. The prescribing office submits a continuation with current data, and a diary entry two months before the end date turns an urgent problem into scheduled paperwork. It belongs at the top of the list as both the most common cause and the least trouble to resolve.
Second: whether the plan year turned over
Plan years do not always follow calendar years. An employer renewing in July changes cost sharing and drug list in the middle of what everyone else calls the year. Two things commonly move at that moment. A deductible reset changes what a member pays without changing whether the product is covered. And a sponsor may have switched benefit managers entirely, which usually invalidates approvals issued under the previous administrator.
An administrator change is worth identifying quickly. Some plans honor existing authorizations through a transition window; others require everything resubmitted. One question to the benefits administrator settles which.
Third: the drug list
Lists get revised on published cycles, sometimes more than once in twelve months, and a revision can take three different shapes. Moving a product between positions changes what the member pays. Attaching a new rule inserts a review that was not there before. Dropping it entirely usually reflects a competing agreement that nets the plan a lower price. Health policy research on rebate flows and on the growth of exclusion practices describes placement turning over faster than members expect.
Plans usually issue advance notice of an unfavorable revision, and many offer continuity arrangements for members already established on the product being dropped. The notice reaches people by mail or through the plan portal, which is the practical case for reading benefit correspondence when it lands rather than stacking it.
Fourth: the dispensing channel
This one gets overlooked. A benefit can keep covering a product while changing where it must be filled, moving a prescription to a mail service, a specialty pharmacy or a narrower retail network. The claim then rejects on network grounds and nothing clinical has changed at all. Where the designated pharmacy sits inside the same corporate group as the benefit manager, that is a contracting arrangement, and published work comparing specialty pharmacies by ownership type has begun documenting how patient populations sort across those channels.
Fifth: the employer’s benefit design
Sponsors add and drop the weight-management category, usually at renewal. When the category goes, every product in the class rejects together and appeals do not help, because no clinical rule was applied to reach that outcome. The diagnostic is simple: if a test claim on a different anti-obesity agent bounces the same way, the category rather than the product is the problem.
| Moving part | Calendar it follows | Notice you should have had | Where to verify it |
|---|---|---|---|
| Member authorization | Fixed term from approval date | The original approval letter | Prescriber’s office or plan portal |
| Deductible and cost sharing | Plan year | Annual benefit summary | Claim history in the portal |
| Drug list | Published revision cycle | Change notice by mail or portal | Current list from the plan |
| Dispensing channel | Contract term | Network change notice | Pharmacy help desk |
| Benefit design | Employer renewal | Open enrollment materials | Benefits administrator |
| Administrator | Contract term | New card and welcome pack | The card itself |
One shift that is not a coverage shift at all
Accumulator and maximizer arrangements catch people out. In those designs, money a manufacturer contributes toward a member’s cost may be excluded from the running total that counts toward a deductible or an annual spending cap. The product stays covered throughout. What moves is the point in the year at which the household starts paying the whole amount, and it lands with no warning attached.
When the category has genuinely been dropped
Losing the category leaves two practical directions. One is the manufacturer’s own self-pay pricing, which keeps an approved product in the cabinet. The other is a compounded GLP-1 provider, where the monthly figure is lower and the supervision attached to it varies a great deal between practices. Compounding sits in its own regulatory category: those preparations carry no FDA approval, and the agency does not assess them for safety, effectiveness or quality before dispensing.
The option that goes unpriced is simply stopping. Participants in the STEP-1 trial extension regained about two-thirds of what they had lost during the twelve months after treatment ended, so a gap in supply is rarely a neutral pause. Published work on how compounded semaglutide is being prescribed, and on obesity pharmacotherapy generally, is a better starting point than treating a benefit change as a signal to stop.
Whichever direction is chosen, the cash market rewards a little shopping around. Monthly prices for Wegovy and its alternatives sit at very different levels across HealthRX, Ro and Hims and Hers, and the gap usually comes down to what each includes for visits, dose changes and follow-up rather than the drug itself. Lining up two or three quotes before committing turns a single advertised figure into something closer to a real annual cost.
Questions people ask
Which of the five deserves the first phone call?
The authorization, every time. It is the cause with the highest base rate, the only one a single office can resolve within a day or two, and the one nobody is told about in advance. Ruling it out costs one call and removes the largest source of confusion from everything that follows.
Does a new card mean previous approvals are void?
Often, though not always. Approvals belong to the organization that issued them, so a change of administrator frequently means resubmitting rather than transferring. Some contracts include a grace window for members already receiving treatment. The benefits administrator can confirm which arrangement is in place, ideally in writing.
Is continuity of supply automatic or does it have to be requested?
It varies. Some plans apply it without being asked when a product they were paying for comes off the list, while others treat it as a request the prescriber has to make. Asking early costs nothing and avoids discovering the answer when a refill is already overdue.
How do you tell a network problem from a coverage problem?
Ask a second pharmacy in a different channel to run the same claim. If it processes there, the issue was where the prescription was sent rather than whether the plan pays. That single test separates a contracting question from a benefit question in about ten minutes.
